Program
anlotinib
Also written as “Anlotinib”, “AL3818” and “AK104+anlotinib”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Endometrial Neoplasms · Small Cell Lung Carcinoma · Neoplasms · Sarcoma, led by 8 companies.
Drug pageAnlotinib: every studyMany companies study it; this page follows only the 40 they lead. All 374 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 311 open or running | phase 3since Dec 30, 2013 | Mar 29, 2013 | none ahead |
| Advenchen Laboratoriesits history only | 32 open or running | phase 3since Aug 28, 2015 | Sep 26, 2014 | Dec 2027phase 3 · NCT03016819 |
| Advenchen Laboratories Nanjingits history only | 11 open or running | phase 1since Feb 11, 2026 | Feb 11, 2026 | Mar 31, 2027phase 1 · NCT07438886 |
| Advenchen Pharmaceuticals, LLC.its history only | 11 open or running | phase 2since Aug 12, 2026 | Aug 12, 2026 | Sep 1, 2030phase 2 · NCT07811297 |
| Akesoits history only | 10 open or running | phase 2since Nov 23, 2020 | Nov 23, 2020 | none ahead |
| Fosun Pharmaits history only | 11 open or running | phase 2since Apr 25, 2026 | Apr 25, 2026 | Jun 2029phase 2 · NCT07562581 |
| Lyvgen Biopharmaits history only | 10 open or running | phase 2since Mar 2, 2022 | Mar 2, 2022 | none ahead |
| Shanghai Gopherwood Biotechits history only | 11 open or running | phase 2since Jan 12, 2023 | Jan 12, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sino Biopharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 17 studies since Mar 29, 2013.
- Jun 29, 2016Phase 1 study in Advanced CancerNCT02825563 · 22 enrolled · China
- Feb 16, 2017Phase 2 study in Small Cell Lung CarcinomaNCT03059797 · 120 enrolled · China
- Feb 27, 2018Phase 2 study in Gastroenteropancreatic Neuroendocrine Tumor G3NCT03457844 · 60 enrolled · China
- Apr 18, 2018Phase 2 study in Bone NeoplasmsNCT03527888 · 40 enrolled · China
- Jan 30, 2019Phase 2 study in Carcinoma, HepatocellularNCT03825705 · 60 enrolled · China
- Aug 26, 20192 phase 3 studiesNCT04073537, NCT04073550
- Sep 25, 2019Phase 2 study in Gastrointestinal Stromal TumorsNCT04106024 · 60 enrolled · China
- Dec 30, 2019Phase 2 study in Advanced MalignancyNCT04216082 · 93 enrolled · China
- Jan 16, 2020Phase 3 study in Extensive Small Cell Lung CancerNCT04234607 · 738 enrolled · China
- Mar 25, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungNCT04325763 · 315 enrolled · China
- Sep 30, 2020Phase 2 study in Advanced Endometrial CancerNCT04574284 · 170 enrolled · China
- Jun 17, 2024Phase 3 study in Small Cell Lung Cancer Limited StageNCT06469879 · 358 planned · China
- Jul 11, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06507891 · 30 enrolled · China
- Nov 16, 2026Primary completion moved from 2027-11 to 2028-12Date moved laterphase 2 · +13 months · NCT07548177
TargetBeta
“Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| regorafenibrule | Bayer | phase 4 | 40 |
Studies
All 31 Sino Biopharmaceutical leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06507891Carcinoma, Non-Small-Cell Lung · China | 2 | Terminated | Aug 25, 2023 | 30 |
| NCT06469879Small Cell Lung Cancer Limited Stage · China | 3 | Not yet recruiting | Sep 2026 | 358 |
| NCT04574284Advanced Endometrial Cancer · China | 2 | Completed | Nov 9, 2023 | 170 |
| NCT04325763Carcinoma, Non-Small-Cell Lung · China | 3 | UNKNOWN | Dec 2022 | 315 |
| NCT04234607Extensive Small Cell Lung Cancer · China | 3 | UNKNOWN | Dec 2022 | 738 |
| NCT04216082Advanced Malignancy · China | 2 | Completed | Aug 31, 2014 | 93 |
| NCT04106024Gastrointestinal Stromal Tumors · China | 2 | UNKNOWN | Oct 30, 2019 | 60 |
| NCT04073550Small Cell Lung Carcinoma · China | 3 | UNKNOWN | Jul 31, 2021 | 184 |
| NCT04073537Squamous Non-small Cell Lung Cancer · China | 3 | UNKNOWN | Jul 31, 2021 | 386 |
| NCT03825705Carcinoma, Hepatocellular · China | 2 | UNKNOWN | Jan 1, 2021 | 60 |
| NCT03527888Bone Neoplasms · China | 2 | UNKNOWN | Dec 31, 2019 | 40 |
| NCT03457844Gastroenteropancreatic Neuroendocrine Tumor G3 · China | 2 | UNKNOWN | Aug 30, 2019 | 60 |
| NCT03059797Small Cell Lung Carcinoma · China | 2 | Completed | Jun 30, 2018 | 120 |
| NCT02825563Advanced Cancer · China | 1 | Completed | Aug 15, 2018 | 22 |
| NCT02809534Carcinoma, Hepatocellular · China | 2 | UNKNOWN | Dec 2017 | 60 |
| NCT02752516Neoplasms · China | 1 | UNKNOWN | Dec 2017 | 16 |
| NCT02649361Esophageal Squamous Cell Carcinoma · China | 2 | Completed | Jul 23, 2018 | 164 |
| NCT02622932Advanced Solid Tumors · China | 1 | Completed | Dec 30, 2016 | 6 |
| NCT02586350Carcinoma, Medullary · China | 3 | Completed | Sep 30, 2018 | 91 |
| NCT02586337Differentiated Thyroid Cancer · China | 3 | UNKNOWN | Dec 2019 | 113 |
| NCT02461407Stomach Neoplasms · China | 3 | UNKNOWN | Dec 2017 | 378 |
| NCT02449343Sarcoma · China | 3 | UNKNOWN | Apr 2017 | 233 |
| NCT02388919Carcinoma, Non-Small-Cell Lung · China | 3 | Completed | Jan 5, 2017 | 439 |
| NCT02332499Colorectal Neoplasms · China | 3 | Completed | Aug 18, 2016 | 419 |
| NCT02072044Carcinoma, Renal Cell · China | 2 | UNKNOWN | Dec 2017 | 60 |
| NCT02072031Anlotinib · China | 2 | UNKNOWN | Dec 2016 | 133 |
| NCT02029209Carcinoma, Non-Small-Cell Lung · China | 3 | UNKNOWN | Mar 2017 | 110 |
| NCT01924195Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | Mar 2015 | 117 |
| NCT01878448Neoplasms · China | 2 | Completed | Oct 2015 | 166 |
| NCT01874873Neoplasms · China | 2 | Completed | Dec 2016 | 58 |
| NCT01833923Advanced Cancer · China | 1 | Completed | Oct 2015 | 35 |
How it is read
Names in the registry
- “Anlotinib”, 27 entries
- “AL3818”, 5 entries
- “AK104+anlotinib”, 3 entries
- “luvometinib + anlotinib”, 2 entries
- “Anlotinib and 14C-labeled Anlotinib”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 7 studies
- Endometrial Neoplasms, 4 studies
- Small Cell Lung Carcinoma, 4 studies
- Neoplasms, 3 studies
- Sarcoma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.